Real‐World Effectiveness of Initial Disease‐Modifying Therapies in Pediatric Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Neurology"
DOI: 10.1002/ana.25737
Abstract: To assess real‐world effectiveness of initial treatment with newer compared to injectable disease‐modifying therapies (DMTs) on disease activity in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS). read more here.
Keywords: real world; effectiveness initial; world effectiveness; modifying therapies ... See more keywords
Trends in the use of disease‐modifying therapies among reproductive‐aged women with multiple sclerosis in the United States from 2010 to 2019
Sign Up to like & getrecommendations! Published in 2022 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.5411
Abstract: Multiple sclerosis (MS) is a chronic disease of the central nervous system that disproportionately affects women, with typical onset during reproductive age. Several disease‐modifying therapies (DMTs) are FDA‐approved to slow disease progression, but are not… read more here.
Keywords: modifying therapies; 2010 2019; disease modifying; multiple sclerosis ... See more keywords
Longitudinal changes of swallowing safety and efficiency in infants with spinal muscular atrophy who received disease modifying therapies
Sign Up to like & getrecommendations! Published in 2024 at "Pediatric Pulmonology"
DOI: 10.1002/ppul.26919
Abstract: Dysphagia is a common feature of the natural history of patients with spinal muscular atrophy (SMA). Literature regarding swallowing safety and efficiency is scarce in patients with SMA, particularly in the era of newborn screening… read more here.
Keywords: spinal muscular; swallowing safety; muscular atrophy; disease modifying ... See more keywords
Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Neurology"
DOI: 10.1007/s00415-024-12366-5
Abstract: Increasingly, patients, clinicians, and regulators call for more evidence on the impact of innovative medicines on quality of life (QoL). We assessed the effects of disease-modifying therapies (DMTs) on QoL in people with multiple sclerosis… read more here.
Keywords: effects disease; quality life; qol; disease modifying ... See more keywords
Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies
Sign Up to like & getrecommendations! Published in 2017 at "PharmacoEconomics"
DOI: 10.1007/s40273-017-0577-2
Abstract: Introduction and objectiveMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. MS is considered incurable; however, disease treatment has advanced significantly over the past several decades with the introduction of disease-modifying… read more here.
Keywords: modifying therapies; cost; disease modifying; cost effectiveness ... See more keywords
Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2020.1795127
Abstract: ABSTRACT Introduction Alzheimer’s disease (AD) is the main cause of dementia and represents a huge burden for patients, carers, and healthcare systems. Extensive efforts for over 20 years have failed to find effective disease-modifying drugs.… read more here.
Keywords: discontinued disease; alzheimer disease; modifying therapies; disease modifying ... See more keywords
The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2016.1258366
Abstract: Abstract Background: The safety and efficacy of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) has been established; however, it is not clear which provides optimal value, given benefit-risk profiles and costs. Aims: To compare… read more here.
Keywords: relapsing remitting; modifying therapies; cost; disease modifying ... See more keywords
Analysis of recent failures of disease modifying therapies in Alzheimer’s disease suggesting a new methodology for future studies
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Neurotherapeutics"
DOI: 10.1080/14737175.2016.1194203
Abstract: ABSTRACT Introduction: Pharmaceutical companies and the NIH have invested heavily in a variety of potential disease-modifying therapies for Alzheimer’s disease (AD) but unfortunately all double-blind placebo-controlled Phase III studies of these drugs have failed to… read more here.
Keywords: methodology; alzheimer disease; modifying therapies; disease modifying ... See more keywords
Disease-modifying therapies for tauopathies: agents in the pipeline
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Neurotherapeutics"
DOI: 10.1080/14737175.2019.1606715
Abstract: ABSTRACT Introduction: Tauopathies are heterogeneous clinicopathological entities characterized by abnormal neuronal and/or glial inclusions of the microtubule-binding protein tau. Primary tauopathies considered to be diseases correspond to a major class of frontotemporal lobar degeneration (FTLD)… read more here.
Keywords: tau; modifying therapies; primary tauopathies; disease modifying ... See more keywords
System Readiness For Disease-Modifying Therapies For Alzheimer’s Disease In Ireland – Challenges And Opportunities
Sign Up to like & getrecommendations! Published in 2025 at "Age and Ageing"
DOI: 10.1093/ageing/afaf318.002
Abstract: The emergence of disease-modifying therapies (DMTs) for Alzheimer’s disease (AD) represents a major shift in treatment, offering hope for patients while presenting considerable challenges for healthcare systems. In Ireland, memory clinics vary widely in service… read more here.
Keywords: alzheimer disease; disease; system; disease modifying ... See more keywords
Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab
Sign Up to like & getrecommendations! Published in 2023 at "BMJ Open"
DOI: 10.1136/bmjopen-2022-067516
Abstract: Objectives Disease-modifying therapies (DMTs) can slow disease progression in multiple sclerosis (MS). The objective of this study was to explore the cost-of-illness (COI) progression among newly diagnosed people with MS in relation to the first… read more here.
Keywords: disability; progression; newly diagnosed; modifying therapies ... See more keywords